NEW YORK (GenomeWeb) – Natera said today that it will join the Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2 (I-SPY 2) clinical trial, a multi-center study evaluating the combination of investigational therapies and neoadjuvant treatment in women with breast cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.